Skip to main content
SNO 28th Annual Meeting Main banner
Final Program


Program
Icon Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
ISS CME
ISS CME
Named Award Winner
Named Award Winner
Award Winner
Award Winner
Poster Award Winner
Poster Award Winner
Back

Biomarkers

Session: Poster Session

BIOM-13 - Association of hand-foot skin reactions with survival in recurrent glioblastoma patients treated with regorafenib

Friday, November 17, 2023
7:30 PM – 9:30 PM PT
Location: Exhibit Hall A/B
Non-CME

    Poster Presenter(s)

  • Jan-Michael Werner

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

    • Author(s)

  • PH

    Peter Hau

    Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg
    Regensburg, Bayern, United States

  • TK

    Thomas Kowalski

    Dept. of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany
    Bochum, Germany

  • HT

    Hannes Treiber

    Dept. of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany
    Goettingen, Germany

  • Patrick Roth

    Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
    Zurich, Zurich, Switzerland

  • Michael M. Wollring

    Inst. of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany
    Juelich, Nordrhein-Westfalen, Germany

  • IS

    Isabelle Stetter

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Germany

  • CT

    Caroline Tscherpel

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • ER

    Elena K. Rosen

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Germany

  • Garry S. Ceccon

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • CC

    Claudia I. Chapuy

    Dept. of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany
    Goettingen, Germany

  • US

    Uwe Schlegel

    Dept. of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum,
    Bochum, Germany

  • Michael Weller

    Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
    Zurich, Zurich, Switzerland

  • GF

    Gereon R. Fink

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • Norbert Galldiks

    Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

Introduction The phase 2 REGOMA trial suggested a survival benefit of the multikinase inhibitor regorafenib for treating patients with glioblastoma at first recurrence. Hand-foot skin reactions (HFSR) following multikinase inhibitor therapy have been reported to predict prolonged overall survival (OS) in patients with solid tumors. The predictive value of HFSR in patients with recurrent glioblastoma undergoing regorafenib therapy remains to be investigated.MethodsFifty-seven patients (age range, 35-77 years) with recurrent IDH-wildtype glioblastomas were retrospectively identified from five centers in Germany and Switzerland. Regorafenib was administered at 160 mg/d for the first three weeks of each 4-week cycle, with individual dose adjustments according to toxicity. Patients were stratified into two groups based on the occurrence of HFSR following regorafenib. Group differences were investigated using the Mann-Whitney rank-sum and Fisher's exact tests. Kaplan-Meier analysis was used for univariate analyses, and the Cox proportional hazards regression model for multivariate analyses.ResultsPatients received a median of two regorafenib cycles (range, 1-14 cycles). Median follow-up after recurrence was 7.0 months (range, 0.6-35.9 months). The median number of previous treatment lines was 2 (range, 1-6 lines). At the time of data analysis, 47 patients (82%) had died. HFSR were observed in 14 out of 57 patients (25%) and associated with a significantly longer OS (10.6 vs. 6.0 months; P=0.040). No significant group differences (HFSR compared to no HFSR) were observed regarding age, the extent of resection, MGMT promoter methylation, Karnofsky performance status, or the number of completed regorafenib cycles (all P >0.05). Cox proportional hazards regression analysis confirmed that HFSR were associated with longer OS (P=0.039; HR, 0.438), independent of age, Karnofsky performance status, and the number of previous treatment lines (all P >0.05). ConclusionOur data suggest that the occurrence of HFSR following regorafenib is associated with longer OS in recurrent glioblastoma patients.